Vertex Pharmaceuticals (MEX:VRTX) Total Stockholders Equity: MXN349,147 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VRTX Vertex Pharmaceuticals Inc MEX:VRTX
94 GF Score
Price MXN8,192.11
GF Value MXN8,905.05
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Total Stockholders Equity?

Vertex Pharmaceuticals MEX:VRTX 94 Total Stockholders Equity is MXN349,147 Mil as of Mar. 2026. GuruFocus rates MEX:VRTX with a GF Score™ of 94/100 and a GF Value™ of MXN8,905.05 (Fairly Valued). The stock has 5 warning signs investors should review.

Vertex Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2026 was MXN349,147 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Vertex Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 was MXN1,373.71. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Vertex Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.10.

Vertex Pharmaceuticals  (MEX:VRTX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Vertex Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(349147.334-0)/254.164
=1,373.71

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Vertex Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 35821.959) / 349147.334
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Total Stockholders Equity Related Terms

Vertex Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Total Stockholders Equity Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 207,191.40 271,242.00 298,414.07 342,233.69 336,090.80

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 337,484.61 323,399.04 317,699.53 336,090.80 349,147.33
MEX:VRTX
94GF Score
Vertex Pharmaceuticals Inc MEX:VRTX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of MXN349,147 Mil mean?
Vertex Pharmaceuticals (MEX:VRTX) has a Total Stockholders Equity of MXN349,147 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Total Stockholders Equity too high?
Vertex Pharmaceuticals' current Total Stockholders Equity is MXN349,147 Mil. Overall, Vertex Pharmaceuticals has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Total Stockholders Equity compare to REGN and RVMD?
Vertex Pharmaceuticals' Total Stockholders Equity of MXN349,147 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Total Stockholders Equity is MXN349,147 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,905.05, compared to a current price of MXN8,192.11 — trading 8% below its estimated fair value. The current Total Stockholders Equity is MXN349,147 Mil. Vertex Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Total Stockholders Equity is MXN349,147 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of MXN8,192.11 is trading 8% below its estimated GF Value™ of MXN8,905.05. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:VRTX:

  • Total Stockholders Equity: MXN349,147 Mil
  • GF Value™: MXN8,905.05 vs. price of MXN8,192.11 (8% below fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
94GF Score

Get the complete analysis for MEX:VRTX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN8,192.11
Price
MXN8,905.05
GF Value